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Objectives: Chronic obstructive pulmonary disease (COPD) is prevalent among 
adults in China and widespread among smokers. This study assessed health out-
comes of COPD-diagnosed smokers vs. never smokers in urban China. MethOds: 
National Health and Wellness Survey (NHWS) 2010 and 2012 China data were ana-
lyzed. NHWS is a mixed-methodology, Internet-based, nationwide survey of adults 
(18+ years) stratified by gender and age to represent the demographic composition 
of urban China. Respondents self-reporting diagnosis with COPD were categorized 
as smoking (including [non]smokers in process of quitting) or never having smoked. 
Respondents reported on health status: SF-36v2-based Mental (MCS) and Physical 
(PCS) Component Summary scores and SF-6D health utilities; productivity loss: 
Work Productivity and Activity Impairment questionnaire-based metrics; and 
resource utilization in the past six months. Regression modeling assessed health 
outcomes as a function of smoking, controlling for demographics, time since diag-
nosis, and comorbidities. Results: Among 1,421 diagnosed with COPD, 51.6% never 
smoked and 35.5% smoked (of whom, 43.8% were attempting to quit). Smokers vs. 
never smokers were more likely to be male (82.4% vs. 36.4%, respectively), recently 
diagnosed with COPD (i.e., 8.56 vs. 11.09 years), employed, wealthier, partnered, 
overweight, and with higher comorbid risk (all p< 0.05). Adjusting for covariates, 
smokers vs. never smokers had lower health utilities (-0.022 points, p< .001), PCS 
(-1.26 points, p= .043), and MCS (-2.85 points, p< .001), and higher rates of absentee-
ism (44.7% greater, p= .002), impairment while working (22.4%, p< .001), overall work 
impairment (22.3%, p< .001), activity impairment (16.5%, p= .002), emergency room 
visits (65.6%, p< .001), hospitalizations (142.9%, p< .001), and provider visits (23.0%, 
p= .038). On average, impairments were greater and more consistently significant 
among females. cOnclusiOns: Even after adjusting for significant baseline dif-
ferences, smokers vs. never smokers with COPD in urban China experienced poorer 
health outcomes, suggesting the importance of secondary prevention of COPD in 
this population, as well as smoking cessation interventions.
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Objectives: The Huntington Quality of Life Instrument (H-QoL-I) is a self-
administered instrument developed specifically to measure the quality of life of 
patients affected by the Huntington’s disease (HD). It was originally developed 
and validated for France and Italy. This study aimed to validate the US version of 
H-QoL-I. MethOds: The H-QoL-I was composed of 11 items organized into 3 dimen-
sions: motor functioning (4), psychology (4) and socializing (3). Item response can be 
chosen among 5 possibilities, depending on frequency or intensity. The instrument 
was translated forwards and backwards by native speakers. A survey was conducted 
with 170 patients. Internal validity was tested, assessing internal consistency, cor-
relation matrix using item/dimension correlation and factorial structure. External 
validation, using Pearson’s correlation, was performed versus clinical dimension 
scores (motor, functional, temper, depression/anxiety), and the EuroQoL 5D (EQ-
5D). Results: The mean (± standard deviation) age of patients was 49 (±14) years 
and 68% were female. The H-QoL-I showed a good reliability despite the item reduc-
tion (Cronbach’s alpha coefficients were higher than 0.8 for the 3 dimensions). 
Factor analysis explained 79% of the total variance and demonstrated the same 
structure as the French and Italian version. Internal consistency was satisfactory 
for all dimensions, ranging from 0.62 to 0.90. The correlation of each item with its 
associated dimension was higher than its correlation with the other dimensions 
(item discriminate validity). The external validity supported the anticipated cor-
relations between each dimension and the clinical and functional dimensions of 
the Huntington Clinical Self-Reported Instrument (H-CSRI) and the EQ-5D index 
score. The correlation between total H-QoL-I score and EQ-5D index score was 
0.76. cOnclusiOns: The H-QoL-I, which has sound psychometric properties, is a 
valid instrument for measuring the disease specific Health Related Quality of Life 
(HRQoL) of patients with HD in the US.
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Objectives: Huntington’s disease (HD) is a chronic degenerative disorder that 
causes movement abnormalities, cognitive deterioration and affective disturbances. 
The Huntington Clinical Self-Reported Instrument (H-CSRI) is the first clinimet-
ric patient assessed scale for patients with HD. It was originally developed and 
validated for France and Italy and then for Spain. The objective of this study is to 
adapt and validate the H-CSRI for US. MethOds: The H-CSRI, previously validated 
questionnaire, included three subscales assessing: the motor (13 five point Likert-
type items in 4 dimensions), functional (7 Yes/No questions) and behavioural ability 
(13 five point Likert type items in 4 dimensions). It was translated forwards and 
backwards by native speakers and then reviewed by local clinicians and adjusted as 
required. 170 patients completed the questionnaire. While face validity was studied 
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Objectives: Cell phone text messaging reminders, via the Short Messaging Service 
(SMS), offers the promise of an efficient technology for the management of chronic 
diseases, such as asthma. This review aims to evaluate the effectiveness of text mes-
sage reminders on adherence to asthma medication by comparing adherence among 
individuals who received text message medication reminders and those who did 
not. MethOds: A systematic review of the literature was conducted to identify pub-
lished studies. Literature search was restricted to English language and no restrictions 
were imposed on the year and country of publication. Medication adherence was 
the primary measure of intervention in eligible studies. Eligible studies had to have 
a control group, and had to assess the impact of text message reminders on medica-
tion adherence. Results: Of the 64 retrieved articles, 4 fulfilled the inclusion criteria. 
Three of these studies were randomized control trials and one was a non-randomized 
control trial. Three of the studies found text message reminders improved medication 
adherence among individuals who received them when compared to those who did 
not. cOnclusiOns: This review adds to the body of literature reviewing the effective-
ness of widely available and instant technologies in the management of disease. Our 
findings suggest that text message reminders can help improve medication adher-
ence among individuals with asthma. Future studies are needed to strengthen the 
evidence on the effectiveness of text message reminders, patient accessibility to this 
technology, and its acceptance by health care providers.
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Objectives: To evaluate patient-reported treatment adherence in patients with 
asthma between two classes of asthma treatments, inhaled corticosteroids (IC) and 
leukotriene modifiers (LM). MethOds: Participants were identified via MediGuard, 
a novel digital patient platform where patients enroll online via the internet to be 
part of a digital patient community. All information was obtained through partici-
pant self-report. Between 2011 through 2013, MediGuard members with asthma 
were invited to complete the Medication Adherence Report Scale (MARS), a patient 
reported outcome (PRO) instrument that measures aspects of medication adherence. 
MARS scores for high versus low adherence (i.e., scores ≥ 20 out of 25 indicate high 
adherence) were compared between the IC and LM groups using logistic regres-
sion analyses, adjusting for demographic variables, disease severity and number 
of concomitant medications. Results: A total of 365 (IC) and 164 (LM) patients 
participated. Age was similar between groups (mean [SD] = 58.7 [13.3] years vs. 
57.7 [10.7] for IC and LM, respectively); and both groups were predominantly female 
(73.8% for IC; 79.0% for LM). Disease severity and number of concomitant medica-
tions taken were similar between IC and LM groups. Ninety-two percent (n= 151) 
of the LM group had high levels of adherence according to the MARS versus 73% 
(n= 265) of the IC group. In multivariable analyses, patients taking LM had 4.6 (95% 
CIs: 2.5-8.5) times the odds of having high adherence to treatment versus patients 
taking IC. cOnclusiOns: These results suggest higher adherence with oral ver-
sus inhaled agents in asthma after controlling for potential confounders. Further 
exploration regarding why adherence differs between these classes is warranted. 
In addition, investigations into how adherence may be enhanced and the impact of 
low adherence on treatment effectiveness should be performed. Providing patients 
with information on adherence could help inform patients’ treatment decisions.
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Objectives: This post-hoc analysis examined the relationship between the 
EQ-5D index and the visual analog scale (VAS), and pulmonary function measured 
using percent predicted forced expiratory volume in 1 second (FEV1), in patients 
with cystic fibrosis (CF) participating in the STRIVE clinical trial. MethOds: In a 
48-week randomized, placebo-controlled study of ivacaftor in patients aged ≥ 12 
years with CF and a G551D-CFTR mutation, the EQ-5D (index and VAS) and FEV1 
were measured directly from patients at baseline, 15 days, 8 weeks, and every 8 
weeks thereafter. The EQ-5D index was calculated using the U.S. preference-based 
algorithm. Pooling assessments and treatments over time, measures were com-
pared among patients with no (FEV1≥ 90%), mild (70-< 90%), moderate (40-< 70%), 
and severe (< 40%) lung dysfunction. Ceiling effects (EQ-5D index= 1 or VAS= 100) 
were also assessed. Results: 121 patients contributed 1214 observations (FEV1: 
157 no lung dysfunction, 419 mild, 572 moderate, 66 severe). Mean index/VAS scores 
decreased with worsening lung function (no lung dysfunction: 0.967/90.0; mild: 
0.949/84.5; moderate: 0.918/75.1; severe: 0.881/66.4). The EQ-5D index and VAS were 
at the ceiling in 67.5% (no lung dysfunction: 80.9%; mild: 73.3%; moderate: 62.1%; 
severe: 45.5%) and 5.6% (no lung dysfunction: 15.9%; mild: 6.9%; moderate: 2.4%; 
severe: 0.0%) of observations, respectively. cOnclusiOns: In a clinical study of 
patients 12 years of age and older with CF and a G551D-CFTR mutation, the EQ-5D 
index and VAS demonstrated monotonic decreases with decreasing FEV1. The EQ-5D 
VAS was more discriminating of CF lung disease severity than the index score. 
Ceiling effects were high, particularly for the EQ-5D index and for patients with no 
lung dysfunction or mildly affected lung function. Both instruments provide com-
plementary health status information; however, the use of the EQ-5D index alone 
may limit characterization of disease burden and health gains in cost-effectiveness 
analyses of CF therapies.
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COPD Instrument (EMSCI) was designed to measure the occurrence and severity 
of early morning symptoms in patients with COPD and the impact of those symp-
toms on activity limitation and rescue medication use. This abstract describes 
the psychometric analysis conducted to examine the EMSCI’s reliability and 
validity. MethOds: Psychometric properties were examined using data from a 
phase 3 clinical trial. Item analyses were conducted using data from the baseline 
week (weekly average) as well as the morning of Day 1 (both time points prior to 
first dose) from a random split half sample, stratified by baseline GOLD status. 
Descriptive statistics, factor analysis, and Rasch model analysis were conducted 
to examine item performance and final items were selected. Test-retest reli-
ability was assessed for the final instrument using intra-class coefficient (ICC). 
Correlations with baseline assessments including the St. George Respiratory 
Questionnaire (SGRQ), Exacerbations of Chronic Obstructive Pulmonary Disease 
Tool - Respiratory Symptoms (EXACT-RS), and forced expiratory volume in 1 
second (FEV1) were used to evaluate concurrent validity. Results: Patients in 
the sample (N= 1663) were aged 40-93 years (mean 63.93 ± 8.89) and 53% male. 
About 31% of patients experienced early morning symptoms that were at least 
moderate in severity on Day 1. A one-factor structure was confirmed with factor 
analysis for symptom severity items. Test-retest reliability was confirmed with 
symptom severity (ICC= 0.84), activity limitation (ICC= 0.85) and rescue medication 
(ICC= 0.62). Concurrent validity was supported by the EMSCI’s significant posi-
tive correlation with both the SGRQ and EXACT-RS. cOnclusiOns: Results sug-
gest that the EMSCI is a reliable and valid instrument to evaluate early morning 
symptoms in COPD and can potentially be used to collect data to support clinical 
study endpoints.
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Objectives: To evaluate the impact of the HEPAiRx® technology on the qual-
ity of life (QoL) and asthma related outcomes for a pediatric asthma popula-
tion. MethOds: The HEPAiRx® is a window mounted patented room-air purifier 
with HEPA filtration for particulate removal and fresh outside air exchange for VOC 
removal that effectively reduces indoor air pollutants that have been associated 
with asthma. It also has built-in heating and air conditioning so the room can be 
isolated from surrounding spaces and contaminants. The intended sample size 
for this study was 25; however three subjects were enrolled due to recruitment dif-
ficulties. The 16-week prospective portion of the study consisted of 4 home visits. 
Health care resources, a daily diary, pulmonary function tests (PFTs), Forced Vital 
Capacity (FVC), Forced Expiratory Volume (FEV1) and QoL outcomes were captured. 
Health care resources were captured retrospectively for the same calendar period 
in the previous year. The validated Pediatric Asthma Quality of Life Questionnaire 
(PAQLQ) and Pediatric Asthma Caregiver Quality of Life Questionnaire (PACQLQ) 
were administered. Results: The PFTs indicated improvement over the prospec-
tive period. FVC mean value improved by 18.6% from baseline to week 16; FEV1 
mean value improved by 22.0%. The PAQLQ instrument indicated an improvement 
in the subjects’ asthma related QoL; the symptom domain score increased by 46.8% 
from baseline to week 16. The overall score increased by 15.5%. PACQLQ assessed 
mean overall score improved by 4.3% for the study period. Health care resources 
were compared for the study period and the corresponding period in the previous 
year. The resources associated with office visits and medications increased from 
retrospective to prospective. No ED visits were captured and laboratory tests were 
minimal. cOnclusiOns: The HEPAiRx® intervention demonstrated significant 
improvements in the HRQoL and PFT domains. The health care resources increased 
from the retrospective to prospective. Additional research is warranted.
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Objectives: Chronic obstructive pulmonary disease (COPD) is a leading cause 
of death and disability in the US. Due to its progressive nature and high preva-
lence, COPD imposes a considerable burden on Medicare and will be important 
to reimbursement under the Affordable Care Act. Evidence suggests that oral 
nutritional supplements (ONS) may be an effective means of improving COPD 
outcomes, but the extent of this effect among aged 65+ Medicare inpatients 
is unclear. MethOds: Analyses were conducted using the Premier Research 
Database on Medicare patients aged 65+ and carrying a primary diagnosis of 
COPD. Propensity score matching was employed to create a one-to-one matched 
sample of ONS and non-ONS episodes. Because ONS were likely to be given to 
patients with poor unobserved health status, instrumental variables (IV) regres-
sion analysis was performed to address selection bias. IV analyses quantified 
the effect of ONS use on length of stay (LOS), episode cost, and the probability 
of 30-day readmission. Covariates included patient and provider characteristics 
and a time trend. Results: Out of 10,322 ONS episodes and 368,097 non-ONS 
episodes, a one-to-one matched sample was created (N= 14,326). IV regression 
analysis indicated that ONS use reduced LOS by 1.88 days (21.5%), from 8.75 to 6.87 
days (p< 0.01). Similarly, episode costs were reduced by $1,570 (12.5%), from $12,523 
to $10,953 (p< 0.01). Among those episodes which could be tracked for follow-up, 
ONS use lowered the probability of 30-day readmission by 13.1%, from 0.335 to 
0.291 (p< 0.01). cOnclusiOns: ONS presents an inexpensive, effective means for 
through item completion, internal validity was evaluated using factorial structure 
and internal consistency. Results: Face validity suggested that the H-CSRI had 
satisfactory psychometric proprieties (missing data up to 20%). There were floor 
effects for 6 items and no item with ceiling effect. Factor analysis explained 84% 
of the total variance and demonstrated acceptable construct validity for the motor 
subscale. The H-CSRI showed an acceptable reliability (Cronbach’s alpha coefficients 
were higher than 0.80). The items internal consistency scores were higher than 0.40 
and the correlations between items and their respective rest-scores in one dimen-
sion were all higher than the correlations with another dimension. cOnclusiOns: 
These data support the validity of the motor and functional scales of the H-CSRI to 
assess the health status for patients with HD in US. A limitation of this study is that 
the behavioural subscale was not assessed because items related to patients were 
not linked with those related to caregivers. Further analyses should be conducted 
to assess the validity of the behavioural subscale.
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Objectives: Infant hospitalizations for lower respiratory tract infections (LRTIs) 
are common in children under one year of age, of which respiratory syncytial 
virus (RSV) is the major cause. The economic impact of infant hospitalizations for 
respiratory infections has proven to be substantial; however the socioeconomic 
burden it has on parents and caregivers is not as well understood. MethOds: 
The Parent Burden Study was a multinational prospective study designed to 
determine the humanistic and economic burden of infant LRTI hospitalizations. 
Canadian data was collected over two consecutive RSV seasons (2010/2011 and 
2011/2012). Direct health care resource utilization data (e.g. length of hospitali-
zation stay (LOS) and intensive care unit (ICU) admission) were obtained from 
medical chart reviews. Lost work productivity was assessed by surveys adminis-
tered to parents at the time of infant discharge using the Work Productivity and 
Activity Impairment questionnaire specific to caregivers of infants hospitalized 
with respiratory illness. Results: 67 infants (54 term, 13 preterm), < 1 year of 
age were included. 100% of infants had a confirmed RSV diagnosis. The mean 
LOS was 5.68 days (5.65 days term, 5.81 days preterm). 13.4% of infants (13% term 
and 15.4% preterm) required ICU admission and 95.5% had supplemental oxygen 
(96.3% term, 92.3% preterm). Among fathers who completed the survey 37 (84%) 
reported they were currently employed. Absenteeism was 51.27%, presenteeism 
(impaired productivity while at work) was 62.70%, and overall work impairment 
was 78.35%. Of mothers who completed the survey 9% reported they were cur-
rently employed. Of working mothers, absenteeism was 27.78%, presenteeism was 
21.43% and overall work impairment was 72.92%. On average, fathers reported 
74.19% daily activity impairment and mothers reported 88.04% due to their child’s 
hospitalization. cOnclusiOns: This study shows that infant hospitalizations 
due to severe RSV result in an economic burden borne by the health care system, 
employers and parents in Canada.
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Objectives: Asthma is the most common chronic disease in children. To date, there 
is no asthma symptom diary suitable for use in pediatric clinical trials of asthma 
therapy to support labeling claims in children. This study was to characterize the 
symptom experiences in children with asthma and their parents/caregivers (par-
ents), to elicit concepts and language surrounding children’s asthma experiences 
directly from children (ages 4-11 years) and parents, to understand the age at which 
children can comprehend and report asthma symptoms. MethOds: Concept elici-
tation interviews were conducted, consistent with the FDA Guidance for Industry 
on Patient-Reported Outcomes. Child and parental perceptions of the asthma 
symptom experiences were elicited from child-parent dyads. Data from interviews 
were analyzed, using a content analysis approach with ATLAS.ti qualitative data 
analysis software. Results: A total of 27 child-parent dyads from sites in the US 
were interviewed. Children and parents were generally consistent in their report-
ing of daytime asthma symptoms; including coughing, wheezing, chest tightness/
discomfort, and shortness of breath. Both children and parents reported that these 
symptoms may also occur at night and lead to nighttime awakenings. Children 
were more aware of chest tightness and discomfort; parents were more aware of 
wheezing, which may be easier to detect by an observer. Younger children were less 
able to accurately describe their symptoms over longer timeframes/recall periods 
than older children. Children and their parents described symptom severity in terms 
of intensity and frequency. Results supported a daily recall of symptoms as most 
appropriate. cOnclusiOns: The qualitative data support the development of an 
observer asthma symptom diary for parents of children 4 years and older with a 
daily recall period. In addition, children 8 years of age and older may also be able to 
accurately report their symptoms on a daily basis.
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Objectives: Early morning symptoms impact the quality of life of patients with 
chronic obstructive pulmonary disease (COPD). The Early Morning Symptoms of 
